https://seekingalpha.com/article/4128751-viking-therapeutics-buy-rumor-buy-news

— — — — —

Viking Therapeutics (VKTX) announced top-line results for its Phase II trial of VK5211 on Nov-28th. Headline data was positive with the study achieving its primary endpoint of demonstrating statistically significant, dose-dependent increases in lean body mass (less head) in all dosage arms, and with zero drug-related serious adverse events (SAEs) being reported.

VK5211 is a powerful selective androgen receptor modulator (SARM) that is being positioned clinically as a potential best-in-class therapy for improving muscle and bone growth. The trial was based around the drug’s initial target indication of elderly patients recovering from a hip fracture – a large, underserved market in which there are approx. 300k hospitalizations per year in the U.S. alone. The trial launched in late 2015 and, after various delays in recruiting patients, was finally completed in summer 2017. The 108-person study was designed to assess increases in lean body mass and was divided into three treatment arms: 0.5mg, 1.0mg, and 2.0mg, as well as a placebo group…

 

 

 

 

 

 

 

— — —

https://seekingalpha.com/article/4122928-viking-therapeutics-fy17-q3-quarterly-update

— — — — —

Viking Therapeutics (VKTX) reported Q3’17 results on Nov-8th after market-hours. Headline results showed a slight earnings “miss” in the quarter as a result of a non-cash charge, however this remains essentially irrelevant in context of both the near-term and long-term investment thesis as the company awaits the release of top-line data from its phase II trial on molecule VK5211. Shares have essentially traded flat since the quarterly release in the $2.20 range; and while this is down materially from the $3+ price level achieved in mid-October, is still higher by ~100% from the summer months…

 

 

 

 

 

— — —